{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:12:46Z","timestamp":1780791166111,"version":"3.54.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T00:00:00Z","timestamp":1688774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T00:00:00Z","timestamp":1688774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s11845-023-03440-4","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T08:02:04Z","timestamp":1689062524000},"page":"165-172","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Longitudinal variation of serum PCSK9 in ulcerative colitis: association with disease activity, T helper 1\/2\/17 cells, and clinical response of tumor necrosis factor inhibitor"],"prefix":"10.1007","volume":"193","author":[{"given":"Jialin","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyan","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengsi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixun","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunzheng","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shupeng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3109-7568","authenticated-orcid":false,"given":"Yuxiang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,8]]},"reference":[{"key":"3440_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41572-020-0205-x","volume":"6","author":"T Kobayashi","year":"2020","unstructured":"Kobayashi T, Siegmund B, Le Berre C et al (2020) Ulcerative colitis. Nat Rev Dis Primers 6:74. https:\/\/doi.org\/10.1038\/s41572-020-0205-x","journal-title":"Ulcerative colitis. Nat Rev Dis Primers"},{"key":"3440_CR2","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.autrev.2014.01.028","volume":"13","author":"K Conrad","year":"2014","unstructured":"Conrad K, Roggenbuck D, Laass MW (2014) Diagnosis and classification of ulcerative colitis. Autoimmun Rev 13:463\u2013466. https:\/\/doi.org\/10.1016\/j.autrev.2014.01.028","journal-title":"Autoimmun Rev"},{"key":"3440_CR3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.7861\/clinmed.2021-0080","volume":"21","author":"JP Segal","year":"2021","unstructured":"Segal JP, LeBlanc JF, Hart AL (2021) Ulcerative colitis: an update. Clin Med (Lond) 21:135\u2013139. https:\/\/doi.org\/10.7861\/clinmed.2021-0080","journal-title":"Ulcerative colitis: an update. Clin Med (Lond)"},{"key":"3440_CR4","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.gtc.2020.07.005","volume":"49","author":"L Du","year":"2020","unstructured":"Du L, Ha C (2020) Epidemiology and Pathogenesis of Ulcerative Colitis. Gastroenterol Clin North Am 49:643\u2013654. https:\/\/doi.org\/10.1016\/j.gtc.2020.07.005","journal-title":"Gastroenterol Clin North Am"},{"key":"3440_CR5","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.dld.2022.01.127","volume":"54","author":"FS Macaluso","year":"2022","unstructured":"Macaluso FS, Orlando A, Papi C et al (2022) Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology. Dig Liver Dis 54:440\u2013451. https:\/\/doi.org\/10.1016\/j.dld.2022.01.127","journal-title":"Dig Liver Dis"},{"key":"3440_CR6","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","volume":"158","author":"JD Feuerstein","year":"2020","unstructured":"Feuerstein JD, Isaacs KL, Schneider Y et al (2020) AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology 158:1450\u20131461. https:\/\/doi.org\/10.1053\/j.gastro.2020.01.006","journal-title":"Gastroenterology"},{"key":"3440_CR7","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.gtc.2020.08.002","volume":"49","author":"A Bhattacharya","year":"2020","unstructured":"Bhattacharya A, Osterman MT (2020) Biologic Therapy for Ulcerative Colitis. Gastroenterol Clin North Am 49:717\u2013729. https:\/\/doi.org\/10.1016\/j.gtc.2020.08.002","journal-title":"Gastroenterol Clin North Am"},{"key":"3440_CR8","doi-asserted-by":"publisher","unstructured":"Rubin DT, Ananthakrishnan AN, Siegel CA et al (2019) ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol 114:384\u2013413. https:\/\/doi.org\/10.14309\/ajg.0000000000000152","DOI":"10.14309\/ajg.0000000000000152"},{"key":"3440_CR9","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.apsb.2020.12.018","volume":"11","author":"Q Xiao","year":"2021","unstructured":"Xiao Q, Li X, Li Y et al (2021) Biological drug and drug delivery-mediated immunotherapy. Acta Pharm Sin B 11:941\u2013960. https:\/\/doi.org\/10.1016\/j.apsb.2020.12.018","journal-title":"Acta Pharm Sin B"},{"key":"3440_CR10","doi-asserted-by":"publisher","unstructured":"Roda G, Jharap B, Neeraj N et al (2016) Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management. Clin Transl Gastroenterol 7:e135. https:\/\/doi.org\/10.1038\/ctg.2015.63","DOI":"10.1038\/ctg.2015.63"},{"key":"3440_CR11","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1093\/ecco-jcc\/jjy004","volume":"12","author":"S Singh","year":"2018","unstructured":"Singh S, George J, Boland BS et al (2018) Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. J Crohns Colitis 12:635\u2013643. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy004","journal-title":"J Crohns Colitis"},{"key":"3440_CR12","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40259-016-0173-6","volume":"30","author":"X Chen","year":"2016","unstructured":"Chen X, Hou J, Yuan Y et al (2016) Adalimumab for Moderately to Severely Active Ulcerative Colitis: A Systematic Review and Meta-Analysis. BioDrugs 30:207\u2013217. https:\/\/doi.org\/10.1007\/s40259-016-0173-6","journal-title":"BioDrugs"},{"key":"3440_CR13","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1080\/1744666X.2017.1243468","volume":"13","author":"D Pugliese","year":"2017","unstructured":"Pugliese D, Felice C, Papa A et al (2017) Anti TNF-alpha therapy for ulcerative colitis: current status and prospects for the future. Expert Rev Clin Immunol 13:223\u2013233. https:\/\/doi.org\/10.1080\/1744666X.2017.1243468","journal-title":"Expert Rev Clin Immunol"},{"key":"3440_CR14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s00395-015-0463-z","volume":"110","author":"R Schulz","year":"2015","unstructured":"Schulz R, Schluter KD, Laufs U (2015) Molecular and cellular function of the proprotein convertase subtilisin\/kexin type 9 (PCSK9). Basic Res Cardiol 110:4. https:\/\/doi.org\/10.1007\/s00395-015-0463-z","journal-title":"Basic Res Cardiol"},{"key":"3440_CR15","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/j.1365-2796.2009.02167.x","volume":"266","author":"SA Mousavi","year":"2009","unstructured":"Mousavi SA, Berge KE, Leren TP (2009) The unique role of proprotein convertase subtilisin\/kexin 9 in cholesterol homeostasis. J Intern Med 266:507\u2013519. https:\/\/doi.org\/10.1111\/j.1365-2796.2009.02167.x","journal-title":"J Intern Med"},{"key":"3440_CR16","doi-asserted-by":"publisher","unstructured":"Wu NQ, Shi HW, Li JJ (2022) Proprotein Convertase Subtilisin\/Kexin Type 9 and Inflammation: An Updated Review. Front Cardiovasc Med 9:763516. https:\/\/doi.org\/10.3389\/fcvm.2022.763516","DOI":"10.3389\/fcvm.2022.763516"},{"key":"3440_CR17","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.atherosclerosis.2017.04.023","volume":"262","author":"ZH Tang","year":"2017","unstructured":"Tang ZH, Peng J, Ren Z et al (2017) New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4\/NF-kappaB pathway. Atherosclerosis 262:113\u2013122. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.04.023","journal-title":"Atherosclerosis"},{"key":"3440_CR18","doi-asserted-by":"publisher","unstructured":"Kim YU, Kee P, Danila D et al (2019) A Critical Role of PCSK9 in Mediating IL-17-Producing T Cell Responses in Hyperlipidemia. Immune Netw 19:e41. https:\/\/doi.org\/10.4110\/in.2019.19.e41","DOI":"10.4110\/in.2019.19.e41"},{"key":"3440_CR19","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1093\/ibd\/izz149","volume":"25","author":"D Yao","year":"2019","unstructured":"Yao D, Dong M, Dai C et al (2019) Inflammation and Inflammatory Cytokine Contribute to the Initiation and Development of Ulcerative Colitis and Its Associated Cancer. Inflamm Bowel Dis 25:1595\u20131602. https:\/\/doi.org\/10.1093\/ibd\/izz149","journal-title":"Inflamm Bowel Dis"},{"key":"3440_CR20","doi-asserted-by":"publisher","unstructured":"Fang C, Luo T, Lin L (2018) Elevation of serum proprotein convertase subtilisin\/kexin type 9 (PCSK9) concentrations and its possible atherogenic role in patients with systemic lupus erythematosus. Ann Transl Med 6:452. https:\/\/doi.org\/10.21037\/atm.2018.11.04","DOI":"10.21037\/atm.2018.11.04"},{"key":"3440_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-022-03204-6","author":"J Cai","year":"2022","unstructured":"Cai J, Jiang Y, Chen F et al (2022) Serum PCSK9 is positively correlated with disease activity and Th17 cells, while its short-term decline during treatment reflects desirable outcomes in ankylosing spondylitis patients. Ir J Med Sci. https:\/\/doi.org\/10.1007\/s11845-022-03204-6","journal-title":"Ir J Med Sci"},{"key":"3440_CR22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13075-020-02386-7","volume":"23","author":"J Frostegard","year":"2021","unstructured":"Frostegard J, Ahmed S, Hafstrom I et al (2021) Low levels of PCSK9 are associated with remission in patients with rheumatoid arthritis treated with anti-TNF-alpha: potential underlying mechanisms. Arthritis Res Ther 23:32. https:\/\/doi.org\/10.1186\/s13075-020-02386-7","journal-title":"Arthritis Res Ther"},{"key":"3440_CR23","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1097\/MCG.0000000000001607","volume":"56","author":"C Marinelli","year":"2022","unstructured":"Marinelli C, Zingone F, Lupo MG et al (2022) Serum Levels of PCSK9 Are Increased in Patients With Active Ulcerative Colitis Representing a Potential Biomarker of Disease Activity: A Cross-sectional Study. J Clin Gastroenterol 56:787\u2013793. https:\/\/doi.org\/10.1097\/MCG.0000000000001607","journal-title":"J Clin Gastroenterol"},{"key":"3440_CR24","doi-asserted-by":"publisher","unstructured":"Schroeder KW, Tremaine WJ, Ilstrup DM (1987) Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 317:1625\u20131629. https:\/\/doi.org\/10.1056\/NEJM198712243172603","DOI":"10.1056\/NEJM198712243172603"},{"key":"3440_CR25","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG et al (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353:2462\u20132476. https:\/\/doi.org\/10.1056\/NEJMoa050516","journal-title":"N Engl J Med"},{"key":"3440_CR26","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1080\/14397595.2016.1211229","volume":"27","author":"JM Bae","year":"2017","unstructured":"Bae JM, Choo JY, Kim KJ et al (2017) Association of inflammatory bowel disease with ankylosing spondylitis and rheumatoid arthritis: A nationwide population-based study. Mod Rheumatol 27:435\u2013440. https:\/\/doi.org\/10.1080\/14397595.2016.1211229","journal-title":"Mod Rheumatol"},{"key":"3440_CR27","doi-asserted-by":"publisher","unstructured":"Xu Q, Ni JJ, Han BX et al (2021) Causal Relationship Between Gut Microbiota and Autoimmune Diseases: A Two-Sample Mendelian Randomization Study. Front Immunol 12:746998. https:\/\/doi.org\/10.3389\/fimmu.2021.746998","DOI":"10.3389\/fimmu.2021.746998"},{"key":"3440_CR28","doi-asserted-by":"publisher","first-page":"781","DOI":"10.3389\/fimmu.2017.00781","volume":"8","author":"R Zhou","year":"2017","unstructured":"Zhou R, Chang Y, Liu J et al (2017) JNK Pathway-Associated Phosphatase\/DUSP22 Suppresses CD4(+) T-Cell Activation and Th1\/Th17-Cell Differentiation and Negatively Correlates with Clinical Activity in Inflammatory Bowel Disease. Front Immunol 8:781. https:\/\/doi.org\/10.3389\/fimmu.2017.00781","journal-title":"Front Immunol"},{"key":"3440_CR29","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.autrev.2013.06.008","volume":"13","author":"R Caporali","year":"2014","unstructured":"Caporali R, Bugatti S, Cavagna L et al (2014) Modulating the co-stimulatory signal for T cell activation in rheumatoid arthritis: could it be the first step of the treatment? Autoimmun Rev 13:49\u201353. https:\/\/doi.org\/10.1016\/j.autrev.2013.06.008","journal-title":"Autoimmun Rev"},{"key":"3440_CR30","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41584-021-00625-y","volume":"17","author":"D Mauro","year":"2021","unstructured":"Mauro D, Thomas R, Guggino G et al (2021) Ankylosing spondylitis: an autoimmune or autoinflammatory disease? Nat Rev Rheumatol 17:387\u2013404. https:\/\/doi.org\/10.1038\/s41584-021-00625-y","journal-title":"Nat Rev Rheumatol"},{"key":"3440_CR31","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41584-019-0356-x","volume":"16","author":"A Sharabi","year":"2020","unstructured":"Sharabi A, Tsokos GC (2020) T cell metabolism: new insights in systemic lupus erythematosus pathogenesis and therapy. Nat Rev Rheumatol 16:100\u2013112. https:\/\/doi.org\/10.1038\/s41584-019-0356-x","journal-title":"Nat Rev Rheumatol"},{"key":"3440_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-023-03323-8","author":"Y Meng","year":"2023","unstructured":"Meng Y, Zheng X, Zhang Z et al (2023) Circulating PCSK9 relates to aggravated disease activity, Th17\/Treg imbalance, and predicts treatment outcome of conventional synthetic DMARDs in rheumatoid arthritis patients. Ir J Med Sci. https:\/\/doi.org\/10.1007\/s11845-023-03323-8","journal-title":"Ir J Med Sci"},{"key":"3440_CR33","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/kjm2.12225","volume":"36","author":"L Lei","year":"2020","unstructured":"Lei L, Li X, Yuan YJ et al (2020) Inhibition of proprotein convertase subtilisin\/kexin type 9 attenuates 2,4,6-trinitrobenzenesulfonic acid-induced colitis via repressing toll-like receptor 4\/nuclear factor-kappa B. Kaohsiung J Med Sci 36:705\u2013711. https:\/\/doi.org\/10.1002\/kjm2.12225","journal-title":"Kaohsiung J Med Sci"},{"key":"3440_CR34","doi-asserted-by":"publisher","first-page":"13780","DOI":"10.1073\/pnas.0706625104","volume":"104","author":"DN Frank","year":"2007","unstructured":"Frank DN, St Amand AL, Feldman RA et al (2007) Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A 104:13780\u201313785. https:\/\/doi.org\/10.1073\/pnas.0706625104","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3440_CR35","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40779-017-0122-9","volume":"4","author":"N Shi","year":"2017","unstructured":"Shi N, Li N, Duan X et al (2017) Interaction between the gut microbiome and mucosal immune system. Mil Med Res 4:14. https:\/\/doi.org\/10.1186\/s40779-017-0122-9","journal-title":"Mil Med Res"},{"key":"3440_CR36","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.atherosclerosis.2019.07.023","volume":"289","author":"MB Morelli","year":"2019","unstructured":"Morelli MB, Wang X, Santulli G (2019) Functional role of gut microbiota and PCSK9 in the pathogenesis of diabetes mellitus and cardiovascular disease. Atherosclerosis 289:176\u2013178. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.07.023","journal-title":"Atherosclerosis"},{"key":"3440_CR37","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1161\/ATVBAHA.115.305688","volume":"35","author":"J Miao","year":"2015","unstructured":"Miao J, Manthena PV, Haas ME et al (2015) Role of Insulin in the Regulation of Proprotein Convertase Subtilisin\/Kexin Type 9. Arterioscler Thromb Vasc Biol 35:1589\u20131596. https:\/\/doi.org\/10.1161\/ATVBAHA.115.305688","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3440_CR38","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/ni.1990","volume":"12","author":"T Krausgruber","year":"2011","unstructured":"Krausgruber T, Blazek K, Smallie T et al (2011) IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat Immunol 12:231\u2013238. https:\/\/doi.org\/10.1038\/ni.1990","journal-title":"Nat Immunol"},{"key":"3440_CR39","doi-asserted-by":"publisher","unstructured":"Katsuki S, P KJ, Lupieri A et al (2022) Proprotein Convertase Subtilisin\/Kexin 9 (PCSK9) Promotes Macrophage Activation via LDL Receptor-Independent Mechanisms. Circ Res 131:873\u2013889. https:\/\/doi.org\/10.1161\/CIRCRESAHA.121.320056","DOI":"10.1161\/CIRCRESAHA.121.320056"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-023-03440-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-023-03440-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-023-03440-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T05:48:51Z","timestamp":1706075331000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-023-03440-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,8]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["3440"],"URL":"https:\/\/doi.org\/10.1007\/s11845-023-03440-4","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,8]]},"assertion":[{"value":"17 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study gained approval from the Ethics Committee of Harbin Traditional Chinese Medicine Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All the participants provided written informed consents.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}